Lumenis Sponsors Endometriosis Fellowship & Course Series in Partnership with the Nezhat Family Foundation and Worldwide EndoMarch to Grow the Community of Endometriosis Experts Worldwide

Lumenis supports tomorrow's leaders in the fight against endometriosis as part of the company's ongoing commitment to elevating awareness and access to care, while enhancing treatment for millions of women worldwide


YOKNEAM, Israel, July 6, 2018 /PRNewswire/ -- Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced that it will be sponsoring a series of educational events centered around endometriosis - an important step forward in increasing awareness and meeting the needs of millions of women and adolescents suffering from the condition. The first Endometriosis Fellowship & Course, held by the Nezhat Family Foundation and Worldwide EndoMarch in July 2018, will offer free education to pre-med and public health undergraduate students ready to take on the challenges of treating this very common condition, which is dramatically underdiagnosed and often misunderstood.

An estimated 200 million women and adolescents worldwide suffer from endometriosis, a disease in which growth of endometrial-like tissue outside the pelvic cavity causes several conditions, including but not limited to chronic pelvic pain, pain during intercourse, increased menstrual bleeding, infertility, and organ dysfunction. Endometriosis affects women's ability to lead active, happy, daily lives and have children. In the past, lack of knowledge about the disease and its symptoms led to delayed diagnosis and mistreatment, but awareness of endometriosis has grown in recent years, in turn resulting in better patient care. Despite the increased awareness, the endometriosis community continues to recognize a major shortage of experts in the field, meaning millions of women and adolescents with the condition still do not have access to accurate diagnosis and treatment.

"Endometriosis affects about 1 in 10 women and adolescents, many of whom suffer for years without a diagnosis. It is a whole-body disease affecting all the organs of the body. Through the Endometriosis Fellowship & Course, we want to engage a new generation of endometriosis experts to increase access to care and help solve this major public health crisis," said Dr. Camran Nezhat, founder of the Nezhat Family Foundation and Worldwide EndoMarch. "One goal for endometriosis is to develop minimally invasive therapies, which is why we are happy to partner with Lumenis, whose FiberLase CO2 laser technology enables us to delicately and precisely remove endometriotic cells while preserving healthy tissue, including reproductive structures."

The first free Endometriosis Fellowship & Course will take place on four consecutive Saturdays (July 7, 14, 21, 28), with two groups of students attending separate locations: the University of California, San Francisco, Mission Bay Campus, and Stanford University's Li Ka Shing Center. Expert speakers will include Dr. Camran Nezhat, inventor of video laparoscopy and the world's leading expert on endometriosis, as well as Dr. Azadeh Nezhat, Dr. Ceana Nezhat, Dr. Michelle Wood, Dr. Linda Guidice, Dr. Jessica Opoku-Anane, and Dr. Megan Burns. During the course, participants will have a rich classroom curriculum as well as opportunities to work with the Lumenis CO2 laser solutions in a hands-on setting. Applicants can register online for the Endometriosis Fellowship & Course on a first-come, first-serve basis. If both locations for the July 2018 course are full, students can email to be added to the waiting list for future dates of the Endometriosis Fellowship & Course, which are currently being planned.

"This is an exciting time in the endometriosis community, when growing awareness of this disease is meeting new growth in technology and patient care," said Brad Oliver, Lumenis Regional President of North and South America. "As the world leader in CO2 lasers, Lumenis is very proud to join dedicated partners like the Nezhat Family Foundation and Worldwide EndoMarch to fuel that momentum, with a strong determination to change the future by educating and inspiring tomorrow's experts in the field."

About Lumenis FiberLase™ for the Treatment of Endometriosis

Lumenis offers FiberLase™, the only high power CO2 laser fiber. Using the Lumenis advanced UltraPulse™ Duo CO2 laser with FiberLase, surgeons can perform minimally invasive procedures to treat endometriosis relieving pain symptoms while preserving fertility - a key objective for many patients. Experts recommend this laparoscopic approach in cases where pain reduction and reduced morbidity are paramount.1

To learn more about Lumenis CO2 Laser technology for the treatment of endometriosis please visit

1. Young S, Burns MK, DiFrancesco L, Nezhat A, Nezhat C. Diagnostic and treatment guidelines for gastrointestinal and genitourinary endometriosis. J Turk Ger Gynecol Assoc. 2017 Dec 15;18(4):200-209.

About Lumenis
Lumenis is the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' groundbreaking products have redefined medical treatments and have set numerous technological and clinical gold standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.

Genevieve Pierce, Pascale Communications
(512) 774-0735


View original content with multimedia:

SOURCE Lumenis Ltd.


Back to news